Isocitrate dehydrogenase (IDH) mutational status is a strong prognostic criterion affecting the natural history of central nervous system (CNS) diffuse gliomas; this was clearly underlined in the 2016 World Health Organization (WHO) classification of CNS tumors and further stressed in the 2021 edition [1,2]. The gene discussed is IDH2; the disease is central nervous system neoplasm.